New monthly shot for schizophrenia enters first human tests
Disease control
Not yet recruiting
This early-stage study tests a single injection of AX251, a long-acting form of an existing schizophrenia medication, in 48 adults with stable schizophrenia. The goal is to measure how the drug moves through the body and check for side effects. Participants will receive one shot …
Phase: PHASE1 • Sponsor: Anxo Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 22, 2026 13:50 UTC